Recent Data from KATHERINE and APHINITY in HER2+ Breast Cancer

Opinion
Video

Following SABCS 2023, Carey K. Anders, MD, reviews recent updates from the KATHERINE and APHINITY clinical trials in HER2+ breast cancer.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content